Grifols (GIFLF) Total Liabilities (2009 - 2025)
Grifols' (GIFLF) quarterly Total Liabilities came in at $14.1 billion in Q4 2025, up 3.06% on a YoY basis from $13.7 billion in Q4 2024, and up 3.06% quarter-over-quarter from $13.7 billion in Q4 2024.
Analysis
Grifols (GIFLF) Total Liabilities (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Total Liabilities for 17 consecutive years, with $14.1 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Total Liabilities rose 3.06% year-over-year to $14.1 billion; the trailing twelve-month figure through Dec 2025 stood at $14.1 billion (up 3.06% YoY), and the FY2025 full-year result was $13.7 billion, up 13182.41% from the prior year.
- Total Liabilities advanced to $14.1 billion in Q4 2025 per GIFLF's latest filing, from $13.7 billion in the prior quarter.
- Across five years, Total Liabilities topped out at $14.5 billion in Q4 2023 and bottomed at $13.5 billion in Q4 2022.
- Historically, Total Liabilities has averaged $13.9 billion across 5 years, with a median of $13.7 billion in 2024.
- The sharpest annual moves came in 2021 and 2024: Total Liabilities jumped 33.65% in 2021, then decreased 5.69% in 2024.
- Over 5 years, Total Liabilities stood at $13.6 billion in 2021, then dropped by 0.81% to $13.5 billion in 2022, then climbed by 7.25% to $14.5 billion in 2023, then retreated by 5.69% to $13.7 billion in 2024, then advanced by 3.06% to $14.1 billion in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $14.1 billion, $13.7 billion, and $14.5 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 14.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 14.10 Bn |
| Dec 31, 2024 | 13.68 Bn |
| Dec 31, 2023 | 14.50 Bn |
| Dec 31, 2022 | 13.52 Bn |
| Dec 31, 2021 | 13.63 Bn |
| Dec 31, 2020 | 10.20 Bn |
| Sep 30, 2020 | 9.97 Bn |
| Mar 31, 2020 | 9.59 Bn |
| Dec 31, 2019 | 9.63 Bn |
| Sep 30, 2019 | 9.73 Bn |
| Dec 31, 2018 | 8.88 Bn |
| Sep 30, 2018 | 8.88 Bn |
| Jun 30, 2018 | 8.91 Bn |
| Mar 31, 2018 | 10.45 Bn |
| Dec 31, 2017 | 8.58 Bn |
| Jun 30, 2017 | 8.28 Bn |
| Dec 31, 2016 | 6.91 Bn |
| Sep 30, 2016 | 6.74 Bn |
| Jun 30, 2016 | 6.92 Bn |
| Mar 31, 2016 | 100.59 Mn |